Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (28)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gerloni, V.
Right arrow Articles by Fantini, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerloni, V.
Right arrow Articles by Fantini, F.
Related Collections
Right arrow Juvenile Idiopathic Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 907-913
© 2001 British Society for Rheumatology

Paediatric Rheumatology

Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study

Paediatric Rheumatology/Series Editor: P. Woo

V. Gerloni, R. Cimaz1,, M. Gattinara, C. Arnoldi, I. Pontikaki and F. Fantini

Rheumatology Department, University of Milan, Centre for Rheumatic Children, Gaetano Pini Institute, Milan and
1 Paediatric Department, Istituti Clinici di Perfezionamento, Milan, Italy

Abstract

Objective. This open prospective trial was performed in order to assess the efficacy and safety of cyclosporin A in the treatment of patients with juvenile chronic arthritis (JCA).

Methods. Thirty-four of the patients enrolled were affected by systemic-onset disease and seven by chronic anterior uveitis associated with JCA. The cyclosporin dose was usually 3–5 mg/kg per day. The average duration of therapy was 1.4 yr, with a maximum of 7.2 yr.

Results. The efficacy of treatment was mainly evident in terms of control of fever and reduction of steroid therapy. The benefits with respect to arthritis, laboratory parameters and uveitis seemed to be less clear-cut. Side-effects were frequent but usually mild or reversible. Sixty-six per cent of the study population withdrew from therapy because of inefficacy or side-effects. Eight systemic patients withdrew from therapy owing to complete remission.

Conclusion. Cyclosporin can be used in the treatment of JCA, its main benefits being the control of fever and a steroid-sparing effect.

KEY WORDS: Cyclosporin, Therapy, JCA, Children, Uveitis, Systemic.

Notes

Correspondence to: R. Cimaz, Paediatric Department, Via Commenda 9, 20122 Milan, Italy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
V Gerloni, I Pontikaki, M Gattinara, and F Fantini
Focus on adverse events of tumour necrosis factor {alpha} blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients
Ann Rheum Dis, August 1, 2008; 67(8): 1145 - 1152.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
P. J. Hashkes and R. M. Laxer
Medical Treatment of Juvenile Idiopathic Arthritis
JAMA, October 5, 2005; 294(13): 1671 - 1684.
[Abstract] [Full Text] [PDF]

Home page
 Br J OphthalmolHome page
J de Boer, N Wulffraat, and A Rothova
Visual loss in uveitis of childhood
Br J Ophthalmol, July 1, 2003; 87(7): 879 - 884.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.